

The invention relates to the influenza vaccine based on the envelope antigenic proteins of influenza virus grown in the culture of animal cells and the method for obtaining the envelope antigenic proteins of influenza virus. The content of the host cell DNA in this vaccine does not exceed 25 pg per one dose of the vaccine.